혈당 측정 기기 시장 : 제품 유형, 기술, 용도, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Glucose Monitoring Devices Market is projected to grow by USD 21.74 billion at a CAGR of 12.81% by 2032.

Glucose monitoring devices are becoming core infrastructure for diabetes management, moving beyond episodic finger-stick testing toward connected, continuous, and clinically actionable glucose data. The public health need is well documented: the World Health Organization estimates that diabetes affected about 830 million people globally in 2022.

The market includes self-monitoring blood glucose meters, test strips, continuous glucose monitoring systems, flash glucose monitoring sensors, integrated CGM platforms, wearable transmitters, mobile applications, and remote patient monitoring workflows. Growth is supported by aging populations, rising type 2 diabetes prevalence, expanded insulin use, broader reimbursement, and the proven clinical value of time-in-range metrics for reducing glycemic variability and improving diabetes care decisions.

Transformative Shifts in the Glucose Monitoring Landscape

The glucose monitoring devices landscape is shifting from reactive measurement to continuous, preventive diabetes care. Continuous glucose monitoring is increasingly embedded in treatment guidelines, with the American Diabetes Association supporting CGM use across many people with type 1 diabetes and insulin-treated type 2 diabetes. In the United States, the Centers for Medicare & Medicaid Services expanded CGM coverage in 2023 to include more insulin users and selected people with problematic hypoglycemia, reinforcing the move from niche technology to standard care.

Regulatory and technology changes are also transforming competition. The U.S. FDA created the integrated continuous glucose monitoring pathway to support interoperable sensors, while Europe's Medical Device Regulation has raised evidence and post-market surveillance expectations. At the same time, smartphone connectivity, cloud analytics, smaller sensors, longer wear times, pharmacy distribution, and remote patient monitoring are improving access, adherence, and patient engagement.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of glucose monitoring devices by converting continuous sensor readings into predictive, personalized, and workflow-ready insights. AI-enabled analytics can support glucose trend forecasting, hypoglycemia and hyperglycemia risk alerts, meal and activity pattern recognition, sensor quality checks, population-level risk stratification, and clinician prioritization in remote monitoring programs. These capabilities are especially relevant as CGM adoption increases the volume of real-world glucose data available for care decisions.

The cumulative impact is a transition from device-centric monitoring to decision-support ecosystems. In automated insulin delivery, glucose sensors already work with control algorithms and insulin pumps to adjust insulin delivery within regulated systems. Industry leaders must pair AI innovation with clinical validation, explainability, cybersecurity, bias testing, human factors evidence, and compliance with software-as-a-medical-device expectations from regulators such as the FDA and European authorities.

Key Regional Insights

Asia-Pacific is a high-priority region because China and India account for some of the world's largest diabetes populations, while Japan, Australia, and South Korea show stronger adoption of advanced CGM through specialist care, digital health infrastructure, diabetes education networks, and reimbursement pathways. North America remains a leading innovation and adoption hub, supported by FDA-cleared technologies, CMS coverage expansion, strong endocrinology networks, pharmacy access, and high awareness of time-in-range management.

Latin America is advancing through private healthcare channels and public-sector diabetes initiatives, with Brazil and Mexico serving as major demand centers for both blood glucose meters and continuous glucose monitoring. Europe benefits from structured diabetes care, CE-marked innovation, national reimbursement decisions, and guideline-driven adoption, although country-level access varies due to health technology assessment and regional purchasing models. The Middle East faces a high diabetes burden, particularly in Gulf economies, creating demand for premium monitoring, digital diabetes clinics, and remote care models. Africa remains access-constrained, with opportunities centered on affordable blood glucose meters, reliable test-strip supply, clinician training, patient education, and scalable mobile health support.

Key Group Insights

ASEAN demand is shaped by rising type 2 diabetes prevalence, expanding urban healthcare access, growing pharmacy networks, and uneven reimbursement, making affordability, education, and distributor partnerships critical. The GCC has high diabetes prevalence and well-funded health systems, supporting adoption of CGM, digital diabetes clinics, preventive screening, and connected care programs. The European Union is influenced by MDR compliance, data protection rules, health technology assessment, national reimbursement decisions, and cross-border digital health priorities.

BRICS markets combine scale with complexity: China and India offer large patient pools and local manufacturing momentum, Brazil expands access through mixed public-private channels, Russia faces procurement and supply constraints, and South Africa anchors demand in sub-Saharan Africa. G7 countries represent advanced reimbursement, regulatory maturity, clinical evidence generation, and early adoption of integrated diabetes technologies. NATO is not a diabetes policy bloc, but its member countries influence cybersecurity expectations, medical supply resilience, procurement discipline, and digital infrastructure standards relevant to connected glucose monitoring devices.

Key Country Insights

The United States leads in CGM innovation, reimbursement expansion, remote patient monitoring, and connected diabetes platforms, while Canada benefits from provincial coverage decisions and strong clinical adoption in type 1 diabetes. Mexico and Brazil show growing demand driven by diabetes prevalence, private care expansion, public health programs, and the need for affordable monitoring. In Europe, the United Kingdom is shaped by NHS guidance and NICE recommendations, Germany by statutory insurance pathways and digital health adoption, France by centralized reimbursement evaluation, Italy and Spain by regional health system purchasing, and Russia by localized procurement and supply-chain considerations.

In Asia-Pacific, China combines a very large diabetes population with domestic medtech manufacturing, hospital-led adoption, and expanding digital health infrastructure, while India requires cost-sensitive devices, broad distribution, clinician training, and education-led engagement to improve routine glucose testing. Japan is characterized by advanced healthcare infrastructure and aging-related diabetes needs, Australia by structured reimbursement and strong diabetes education networks, and South Korea by technology readiness, hospital integration, smartphone penetration, and digital health adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated CGM and blood glucose monitoring portfolios that address both premium and affordability segments. Interoperability with insulin pumps, electronic health records, mobile applications, pharmacy workflows, and remote patient monitoring platforms should be treated as a competitive requirement rather than an optional feature.

Companies should invest in AI governance, cybersecurity, post-market evidence, human factors testing, and real-world outcomes that demonstrate improved time in range, fewer hypoglycemic events, better adherence, and improved care-team efficiency. Market access strategies must be localized by reimbursement status, diabetes burden, pharmacy reach, clinician training needs, and digital infrastructure maturity, while supply-chain resilience for sensors, semiconductors, enzymes, adhesives, batteries, and test strips remains essential.

Research Methodology

Research methodology is based on secondary research and triangulation from authoritative public sources, including the World Health Organization, International Diabetes Federation, U.S. Centers for Disease Control and Prevention, U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, American Diabetes Association, NICE, OECD, World Bank health indicators, peer-reviewed clinical literature, and national diabetes or reimbursement bodies.

The methodology emphasizes verified epidemiology, regulatory developments, reimbursement policies, clinical guideline direction, technology adoption signals, and digital health readiness across regions and countries. Insights were synthesized using market-structure analysis, demand-driver assessment, technology trend evaluation, policy review, and geographic comparison to support leader-relevant and decision-ready content on glucose monitoring devices.

Conclusion

Glucose monitoring devices are central to the future of diabetes care as health systems shift toward continuous data, earlier intervention, and digitally connected chronic disease management. Rising diabetes prevalence, expanded CGM reimbursement, AI-enabled analytics, remote monitoring, and interoperability standards are strengthening the role of monitoring technologies in both clinical and home settings.

The strongest opportunities will belong to organizations that combine accurate sensors, affordable access, regulatory discipline, secure data ecosystems, reliable supply chains, and evidence-based outcomes. As adoption widens across developed and emerging markets, glucose monitoring devices will remain a foundational category in precision diabetes management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Glucose Monitoring Devices Market, by Product Type

• 7.1. Self-Monitoring Blood Glucose (SMBG) Devices
  • 7.1.1. Blood Glucose Meters
  • 7.1.2. Test Strips
  • 7.1.3. Lancets
• 7.2. Continuous Glucose Monitoring (CGM) Systems
  • 7.2.1. Real-Time CGM
  • 7.2.2. Intermittently Scanned CGM
  • 7.2.3. Sensors
• 7.3. Professional / Clinical Point-of-Care Devices
• 7.4. Non-Invasive Glucose Monitoring Devices

8. Glucose Monitoring Devices Market, by Technology

• 8.1. Invasive
  • 8.1.1. Colorimetric
  • 8.1.2. Electrochemical Amperometric
• 8.2. Minimally Invasive
• 8.3. Non Invasive
  • 8.3.1. Optical Spectroscopy
  • 8.3.2. Transdermal Extraction

9. Glucose Monitoring Devices Market, by Application

• 9.1. Gestational Diabetes
• 9.2. Type 1 Diabetes
• 9.3. Type 2 Diabetes

10. Glucose Monitoring Devices Market, by End User

• 10.1. Ambulatory Care
• 10.2. Home Care
• 10.3. Hospitals
  • 10.3.1. Private Hospitals
  • 10.3.2. Public Hospitals

11. Glucose Monitoring Devices Market, by Distribution Channel

• 11.1. Online Stores
  • 11.1.1. Company Websites
  • 11.1.2. E Commerce Platforms
• 11.2. Offline

12. Glucose Monitoring Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Glucose Monitoring Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Glucose Monitoring Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. ACON Laboratories, Inc.
• 16.3. AgaMatrix, Inc.
• 16.4. ARKRAY, Inc.
• 16.5. Ascensia Diabetes Care Holdings AG
• 16.6. B. Braun Melsungen AG
• 16.7. Beta Bionics, Inc.
• 16.8. Beurer GmbH
• 16.9. Bionime Corporation
• 16.10. Dexcom, Inc.
• 16.11. DiaMonTech AG
• 16.12. F. Hoffmann-La Roche Ltd
• 16.13. ForaCare, Inc.
• 16.14. GlySens Incorporated
• 16.15. i-SENS, Inc.
• 16.16. Insulet Corporation
• 16.17. LifeScan IP Holdings, LLC
• 16.18. Medtronic plc
• 16.19. MicroPort Scientific Corporation
• 16.20. Nemaura Medical Inc.
• 16.21. Nipro Corporation
• 16.22. Nova Biomedical Corporation
• 16.23. Novo Nordisk A/S
• 16.24. Omron Healthcare Co., Ltd.
• 16.25. Prodigy Diabetes Care, LLC
• 16.26. Rossmax International Ltd.
• 16.27. Sanofi S.A.
• 16.28. Senseonics Holdings, Inc.
• 16.29. Sinocare Inc.
• 16.30. TaiDoc Technology Corporation
• 16.31. Tandem Diabetes Care, Inc.
• 16.32. Terumo Corporation
• 16.33. Trividia Health, Inc.
• 16.34. WaveForm Technologies, Inc.
• 16.35. Ypsomed Holding AG